-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Nanjing Chia Tai Tianqing Pharmaceutical submitted a clinical application for ramelteon tablets, which is the company's first drug clinical application submitted this year
.
It is understood that Ramelteon is an oral hypnotic drug developed by Takeda, Japan
.
It is mainly used to treat insomnia that is difficult to fall asleep, and it also has definite curative effect on chronic insomnia and short-term insomnia
.
At present, the original research drug has not been imported in China, but its global sales in 2018 have reached 19.
1 billion yen
.
It is worth mentioning that, in addition to Nanjing Chia Tai Tianqing, there are more than 10 domestic pharmaceutical companies that have obtained clinical approval for ramelteon tablets.
Among them, Yueyang Pharmaceutical Development (Guangzhou) submitted ramelteon in 2021.
The 2.
2 class new drug clinical application for teminide double-release tablets was obtained and the clinical approval was obtained
.
As early as 2017, China Resources Double-Crane Limin Pharmaceutical (Jinan) Co.
, Ltd.
, a holding subsidiary of China Resources Double-Crane Pharmaceutical Co.
, Ltd.
, has also received the ramelteon API approved and issued by the State Food and Drug Administration.
Approval Notice" and Ramelteon Tablets "Drug Clinical Trial Approval"
.
It is worth noting that, in fact, in recent years, with the continuous advancement of volume procurement and the removal of the super-national treatment of original research drugs from the altar, as well as the continuous increase of domestic pharmaceutical companies' investment in innovation, domestic pharmaceutical companies are accelerating their rush for food.
The original drug market
.
As of February 18 this year, the website of the State Food and Drug Administration showed that the supplementary application for Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed
.
According to data, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan.
After the launch of the Linezolid Glucose Injection of the Industry Group, it will also have a greater impact on the Pfizer market
.
In addition, sildenafil is a large-scale product in the ED market, and retail pharmacies are its main sales channel.
In 2019, the terminal sales of retail pharmacies in Chinese cities exceeded 2.
3 billion yuan
.
In 2020, the terminal sales of physical pharmacies in Chinese cities exceeded 2.
5 billion yuan, a year-on-year increase of 8.
57%
.
It is worth mentioning that, with the efforts of local companies, the market share of its original researcher, Pfizer, has continued to decline, from 52.
60% in 2017 to 44.
08% in 2020
.
It is reported that from 2014 to April 2020, there were 13 approved sildenafil products and 9 approved tadalafil products by local enterprises in China
.
The industry believes that this is mainly due to the rapid increase in the volume of generic drugs that continues to promote the rapid growth of the market scale of China's anti-ED drug industry.
As more and more domestic drugs are launched, the market share of the original research drug will continue to decline
.
In general, with the continuous improvement of the innovation strength of domestic pharmaceutical companies, the development of the high-quality drug market will continue to accelerate.
As more and more high-quality generic drugs and innovative drugs emerge in the industry, more and more The multi-origin drug market is expected to be seized by local companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that Ramelteon is an oral hypnotic drug developed by Takeda, Japan
.
It is mainly used to treat insomnia that is difficult to fall asleep, and it also has definite curative effect on chronic insomnia and short-term insomnia
.
At present, the original research drug has not been imported in China, but its global sales in 2018 have reached 19.
1 billion yen
.
It is worth mentioning that, in addition to Nanjing Chia Tai Tianqing, there are more than 10 domestic pharmaceutical companies that have obtained clinical approval for ramelteon tablets.
Among them, Yueyang Pharmaceutical Development (Guangzhou) submitted ramelteon in 2021.
The 2.
2 class new drug clinical application for teminide double-release tablets was obtained and the clinical approval was obtained
.
As early as 2017, China Resources Double-Crane Limin Pharmaceutical (Jinan) Co.
, Ltd.
, a holding subsidiary of China Resources Double-Crane Pharmaceutical Co.
, Ltd.
, has also received the ramelteon API approved and issued by the State Food and Drug Administration.
Approval Notice" and Ramelteon Tablets "Drug Clinical Trial Approval"
.
It is worth noting that, in fact, in recent years, with the continuous advancement of volume procurement and the removal of the super-national treatment of original research drugs from the altar, as well as the continuous increase of domestic pharmaceutical companies' investment in innovation, domestic pharmaceutical companies are accelerating their rush for food.
The original drug market
.
As of February 18 this year, the website of the State Food and Drug Administration showed that the supplementary application for Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed
.
According to data, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan.
After the launch of the Linezolid Glucose Injection of the Industry Group, it will also have a greater impact on the Pfizer market
.
In addition, sildenafil is a large-scale product in the ED market, and retail pharmacies are its main sales channel.
In 2019, the terminal sales of retail pharmacies in Chinese cities exceeded 2.
3 billion yuan
.
In 2020, the terminal sales of physical pharmacies in Chinese cities exceeded 2.
5 billion yuan, a year-on-year increase of 8.
57%
.
It is worth mentioning that, with the efforts of local companies, the market share of its original researcher, Pfizer, has continued to decline, from 52.
60% in 2017 to 44.
08% in 2020
.
It is reported that from 2014 to April 2020, there were 13 approved sildenafil products and 9 approved tadalafil products by local enterprises in China
.
The industry believes that this is mainly due to the rapid increase in the volume of generic drugs that continues to promote the rapid growth of the market scale of China's anti-ED drug industry.
As more and more domestic drugs are launched, the market share of the original research drug will continue to decline
.
In general, with the continuous improvement of the innovation strength of domestic pharmaceutical companies, the development of the high-quality drug market will continue to accelerate.
As more and more high-quality generic drugs and innovative drugs emerge in the industry, more and more The multi-origin drug market is expected to be seized by local companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
